Si-Yang Liu, MD, Guangdong Lung Cancer Institute, Guangzhou, China, describes current efforts in discovering novel targets for non-small cell lung cancer (NSCLC) therapies. Tyrosine kinase inhibitors are a promising class of drugs in advanced NSCLC, and KRAS has been additionally effective in the perioperative space. Further clinical trials are needed to further investigate the optimal combination of chemotherapy, immunotherapy, and targeted therapies for patients. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.